Original article
The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis
Seguridad y eficacia de tolvaptan en el tratamiento de los pacientes con enfermedad renal poliquística autosómica dominante: Revisión sistemática y metaanálisis
a Division of Nephrology, The First College of Clinical Medical Science, Three Gorges University, Yichang, Hubei, China
b Division of Endocrinology, The Renhe Hospital of Three Gorges University, Yichang, Hubei, China
c Division of Urinary Surgery, The First College of Clinical Medical Science, Three Gorges University , Yichang, Hubei, China
Read
2997
Timeswas read the article
1198
Total PDF
1799
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 99 | 80 | 179 |
| 2024 October | 155 | 80 | 235 |
| 2024 September | 127 | 66 | 193 |
| 2024 August | 139 | 96 | 235 |
| 2024 July | 131 | 43 | 174 |
| 2024 June | 144 | 82 | 226 |
| 2024 May | 149 | 91 | 240 |
| 2024 April | 126 | 51 | 177 |
| 2024 March | 108 | 47 | 155 |
| 2024 February | 93 | 64 | 157 |
| 2024 January | 42 | 35 | 77 |
| 2023 December | 40 | 31 | 71 |
| 2023 November | 61 | 77 | 138 |
| 2023 October | 76 | 80 | 156 |
| 2023 September | 68 | 64 | 132 |
| 2023 August | 70 | 48 | 118 |
| 2023 July | 60 | 60 | 120 |
| 2023 June | 78 | 38 | 116 |
| 2023 May | 33 | 65 | 98 |
Show all
